An observational study in Atrial Fibrillation (AF), Cardiomyopathy, Secondary and Pacing-Induced Cardiomyopathy, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 8 under way, none of them phase 3. Atrial Fibrillation · Insel Gruppe AG, University Hospital Bern.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, this one is one of 3 that started in 2011, is one of 9 observational ones, and was the 19th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern are open now, in 10 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, Germany, New Zealand and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, France, Germany and 6 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–85
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,600 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 208 across the 10 interventional studies, 60 across the 9 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrioventricular node ablation with permanent pacing (the "pace-and-ablate" strategy) controls ventricular rate in atrial fibrillation that has not responded to drug therapy or catheter ablation. Chronic right ventricular pacing, however, can cause pacing-induced cardiomyopathy (PICM), and it is not well established which patients are at risk and should therefore receive conduction system pacing or biventricular pacing instead.
REPACE is a multicentre retrospective cohort of consecutive patients who underwent atrioventricular node ablation from January 2011 onwards at five centres in Switzerland, the United Kingdom and Poland: Liverpool Heart and Chest Hospital, Inselspital Bern, University Hospital Basel, Geneva University Hospitals and the Silesian Centre for Heart Diseases, Zabrze. More than 2,000 patients ablated up to March 2024 have been included to date; patients ablated after that date at the participating centres are being added.
The study has three aims: to validate, in an independent multicentre population, a previously published risk model for pacing-induced cardiomyopathy; to describe the procedural technique and outcomes of atrioventricular node ablation across different health systems; and to estimate the health-economic impact of the pace-and-ablate strategy.
Pacing-induced cardiomyopathy is defined as an absolute reduction in left ventricular ejection fraction of at least 10 percentage points to a value below 50%. All potential endpoints are adjudicated by a clinical events committee blinded to the classification made at the site.
Data collection. Baseline demographics, comorbidity, device and procedural data, electrocardiographic and echocardiographic measurements, follow-up events and mortality were abstracted from hospital records at each participating centre into a central electronic case report form.
Endpoint adjudication. Every potential endpoint is reviewed by two independent adjudicators blinded to the classification made at the site, with a third reviewer consulted where they disagree. Pacing-induced cardiomyopathy is assessed on every adjudicated event, independently of how that event is otherwise classified.
Analysis populations. The validation of the risk model is performed in the patients who had neither cardiac resynchronisation therapy nor conduction system pacing at baseline, because a decline in left ventricular function in an already resynchronised patient represents non-response to resynchronisation rather than pacing-induced cardiomyopathy. Patients with resynchronisation at baseline are described and contribute to the procedural and health-economic analyses. No lower limit of baseline ejection fraction is applied: since the definition requires a fall of at least 10 percentage points to a value below 50%, patients already below 50% at baseline can meet it.
Health-economic analysis. Direct costs are derived from Hospital Episode Statistics in the United Kingdom, individual procedure costs from the SwissEPnet registry for Switzerland, and diagnosis-related group and hospital costs for Switzerland and Poland, covering hospital charges, device costs and subsequent care for complications and follow-up. Cost-utility and cost-effectiveness analyses use Markov models to compare pacing strategies.
Consecutive adults with symptomatic atrial fibrillation refractory to drug therapy or catheter ablation who underwent atrioventricular node ablation as part of a pace-and-ablate strategy at five participating centres in Switzerland, the United Kingdom and Poland from January 2011 onwards.
Retrospective inclusion is covered by general consent to the further use of health-related data where this is on file. For deceased or uncontactable patients with no documented refusal, inclusion is covered by the exception from consent under Article 34 of the Swiss Human Research Act (Absence of informed consent), the project having been approved by the Kantonale Ethikkommission Bern. The United Kingdom site operates under IRAS 314643.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Documented refusal of the further use of health-related data
Note: cardiac resynchronisation therapy or conduction system pacing at baseline is not an eligibility exclusion. Such patients are included in the cohort and in the procedural and health-economic analyses, but are excluded from the validation of the pacing-induced cardiomyopathy risk model, in which a decline in left ventricular function would represent non-response to resynchronisation. No lower limit of baseline is applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive adults with atrial fibrillation who underwent atrioventricular node ablation with a permanent cardiac implantable electronic device at the five participating centres from January 2011 onwards. Within this cohort, the patients who had neither cardiac resynchronisation therapy nor conduction system pacing at baseline form the population for the validation of the pacing-induced cardiomyopathy risk model.
Incidence of pacing-induced cardiomyopathy (PICM)
Proportion of patients who develop PICM, defined as an absolute reduction in left ventricular ejection fraction (LVEF) of at least 10 percentage points to a value below 50% on echocardiography after atrioventricular node ablation with ventricular pacing. Each potential event is adjudicated by two independent reviewers blinded to the classification made at the site, with a third reviewer consulted in case of disagreement.
Time frame: From atrioventricular node ablation up to 10 years
All-cause mortality by pacing modality
Proportion of patients who die from any cause, reported separately for right ventricular pacing, biventricular pacing and conduction system pacing.
Time frame: From atrioventricular node ablation up to 5 years
Heart failure hospitalisation by pacing modality
Proportion of patients with at least one hospitalisation for heart failure, reported separately for right ventricular pacing, biventricular pacing and conduction system pacing.
Time frame: From atrioventricular node ablation up to 5 years
Acute procedural success of atrioventricular node ablation
Proportion of procedures with complete atrioventricular block at the end of the procedure, i.e. intended loss of atrioventricular conduction with transition to ventricular pacing.
Time frame: Periprocedural (index atrioventricular node ablation)
Use of a second ablation catheter, by type of first ablation catheter (irrigated versus non-irrigated)
Proportion of procedures in which a second ablation catheter was required to achieve atrioventricular block, reported separately for procedures started with an irrigated and with a non-irrigated catheter.
Time frame: Periprocedural (index atrioventricular node ablation)
Presence of a ventricular escape rhythm after atrioventricular node ablation
Proportion of patients with a ventricular escape rhythm documented at the end of the atrioventricular node ablation procedure.
Time frame: Periprocedural (index atrioventricular node ablation)
Procedure duration by use of a long sheath
Duration of the atrioventricular node ablation procedure in minutes, reported separately for procedures performed with and without a long sheath.
Time frame: Periprocedural (index atrioventricular node ablation)
Cumulative direct healthcare costs per patient
Cumulative direct healthcare costs per patient in euros, covering the index procedure (hospital stay, device and consumables) and subsequent hospital care for complications and follow-up. Costs are derived from Hospital Episode Statistics (United Kingdom), the SwissEPnet registry and diagnosis-related group data (Switzerland, Poland) and converted to euros.
Time frame: From atrioventricular node ablation up to 5 years
Incremental cost-effectiveness ratio of conduction system pacing versus right ventricular pacing
Incremental cost per quality-adjusted life-year (QALY) gained, estimated with a Markov model from the observed event rates and direct healthcare costs, overall and across strata of predicted pacing-induced cardiomyopathy risk and of procedural complexity.
Time frame: From atrioventricular node ablation up to 5 years
Return to sinus rhythm during follow-up
Proportion of patients with documented return to sinus rhythm on electrocardiogram or device interrogation after atrioventricular node ablation.
Time frame: From atrioventricular node ablation up to 5 years
Discrimination of the published and of an updated pacing-induced cardiomyopathy risk model (C-statistic)
C-statistic (area under the receiver operating characteristic curve) for predicting pacing-induced cardiomyopathy, reported for the previously published risk model as originally specified and for a model updated in this cohort (recalibration and re-estimation of predictor weights, with candidate additional predictors), in patients without cardiac resynchronisation therapy or conduction system pacing at baseline.
Time frame: From atrioventricular node ablation up to 10 years
Incremental cost-effectiveness ratio of biventricular pacing versus right ventricular pacing
Incremental cost per quality-adjusted life-year (QALY) gained, estimated with a Markov model from the observed event rates and direct healthcare costs, overall and across strata of predicted pacing-induced cardiomyopathy risk and of procedural complexity.
Time frame: From atrioventricular node ablation up to 5 years
Started Jan 2011 (actual). Primary completion is estimated for Jun 2027, 197 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →